Expansion of the Territory. The parties hereby acknowledge and agree -------------------------- that, as of the Effective Date, the Territory shall be limited to the U.S. Cytogen hereby grants to Bard a right of first offer to expand the Territory to include one (1) or more of the Selected Countries, subject to relinquishment by CIS and Faulding of their respective rights of first negotiation to market and promote Product to Urologists in the Selected Countries. In the event CIS notifies Cytogen that it relinquishes its said right of first negotiation with respect to one or more of the Selected Countries (other than Canada) or in the event Faulding notifies Cytogen that it relinquishes its said right of first negotiation with respect to Canada (a "Waiver Notice"), Cytogen, within thirty (30) business days of its
Expansion of the Territory. Sankyo is hereby granted options to add Japan and the European Union (which shall mean those countries which make up the European Union as of the Effective Date and the additional countries of Norway and Switzerland) to the Territory. The options for Japan and the European Union shall individually expire on [ * ]. Should Sankyo decide to so expand the Territory, it shall provide GelTex with written notice of such decision prior to the expiration of the option, and following GelTex's receipt of such written notice, the definition of the Territory shall be revised to include the additional countries and/or territories specified in such notice. As part of its due diligence obligations Sankyo shall be required to: (i) commence Phase I clinical trials of Compound in Japan within [ * ] of adding Japan to the Territory; and (ii) file a Marketing Authorization Application in the European Union (or equivalent regulatory submissions in at least two countries of the European Union designated by the mutual agreement of the Parties) within [ * ] after the NDA for Compound is filed in the United States. If Sankyo fails to meet either of the due diligence [ * ] Confidential information omitted and filed separately with the Commission.
(i) the territory in which the obligation was not meet will be removed from the definition of the Territory, and Sankyo shall no longer have any rights to Compound in such territory; (ii) Sankyo promptly shall deliver to GelTex all data, information and material that it may have regarding the clinical, non-clinical and regulatory development, manufacture, marketing, and sale of Compound in such territory; and (iii) Sankyo shall not be entitled to receive reimbursement for a percentage of Development Costs under Section 5.2.3.
Expansion of the Territory. Should the Company wish to expand the Territory to include lsrael, Cyprus and/or any other country in the Middle East, the Licensors shall favorably consider such request, provided that the Company shall grant Hadasit a right of first refusal to set up treatment centers, with the use of the Products, in any such countries.
Expansion of the Territory. Licensor shall provide to Licensee a right of first refusal on any license proposed to be granted by Licensor to any third party for use of the Technology outside the Territory but in the Industry, affording Licensee the opportunity to extend the Territory on terms and conditions at least as favorable as those proposed to be granted under the proposed transaction. In addition, Licensor shall expand the Territory upon written request of Licensee, provided (a) Licensor has not granted rights to any third party in the geographic area requested, and (b) Licensee can make a commercially reasonable showing that that Licensee has a bona fide business opportunity in such region. In the event Licensee is not successful in consummating a sublicense of the Technology hereunder in such expanded Territory, such region shall revert to Licensor in a reasonable time.
Expansion of the Territory. Distributor shall have the right, at any time from the Effective Date through December 31, 2025 to request that Regenity submits for regulatory clearance(s) of the Products in the countries of the European Union, as well as Australia and Japan. The submission of these regulatory filings shall be reflected through a Statement of Work to be attached to this Agreement, executed by the Parties, by no later than December 31, 2025. Upon regulatory approval, the expansion of the Territory shall be reflected through an amendment of Schedule B. Distributor’s Exclusive Distribution rights in the Territory as expanded in accordance with this section 2.3(b) shall remain in place for the Term unless its distribution rights are terminated in accordance with the provisions of this Agreement. (The obligations of, and limitations on, Distributor under this Section 2.3 are referred to collectively as Distributor’s “Territory Commitment”).
Expansion of the Territory. 5.1 PharmaPrint hereby grants AHP, and AHP accepts, an option to expand the Territory to further include any countries other than the United States of America.
5.2 Such option may be exercised by AHP in its sole discretion at any time during a period of three (3) years commencing upon the initial National Launch Date within the Territory ("Option Period") through the provision by AHP to PharmaPrint of notice of such exercise in conformance with the notice provisions of this Agreement.
Expansion of the Territory. (a) During the Term, [***] shall have [***] to obtain [***] in the [***]. Epirus shall [***] with any [***] to obtain [***] in the [***]. In the event that Epirus and Ranbaxy have [***] pursuant to which [***] such a [***] in the [***], Epirus shall [***] for the [***] in the [***].
(b) If either Party desires to expand the Territory to include other countries outside of the Territory or the Additional Territory during the Term, such Party shall [***] to the [***], as applicable, [***]. The Parties shall [***] following the [***] whether Epirus is [***], and the [***] that may [***], including, without limitation, the [***] between the Parties with respect to any [***], and the [***].
Expansion of the Territory. At any time during the initial twelve (12) months of the Term of this Agreement, WYETH shall have the right and option to negotiate for the addition of countries or geographic areas to the Territory. Such right is exercisable by delivery of written notice to ACCESS, specifying the countries or geographic areas with respect to which WYETH would like to add to the Territory, and is subject to mutual agreement of the Parties. Upon receipt of such notice, the Parties shall negotiate in good faith the terms of the exclusive or non- exclusive (as the parties may mutually agree) arrangement with respect to the additional countries or geographic areas. In the event that the Parties are unable to reach agreement on such terms on or prior to the 60th day following commencement of such negotiations, ACCESS shall bear no further obligation to WYETH under this Section 2.7 with respect to the applicable countries or geographic area; provided that ACCESS shall not thereafter enter into or be a party to any arrangement, agreement, license or distribution relationship with a Third Party with respect to the Product in all or any portion of the applicable countries or geographic areas on terms and conditions in the aggregate more favorable to such Third Party than the aggregate terms and conditions offered to WYETH without first offering such aggregate terms and conditions to WYETH.
Expansion of the Territory. Nextel shall have the option, at anytime during the term of this Agreement, to expand the Territory subject to the terms of this Section 2.
Expansion of the Territory. Under Section 1.60 of the Current Agreement, the Territory is defined as “the U.S., Canada, and Mexico and their respective territories, protectorates and possessions.” On the Amendment Effective Date, the Territory as defined in the Current Agreement (the “Original Territory”), and the license granted to Catalyst under Section 2.1 of the Current Agreement, shall be expanded to include, Japan and its territories, protectorates and possessions. Further, upon acceptance by the MHLW of a Japan MAA for a Licensed Product for LEMS, the Territory, and the license granted to Catalyst under Section 2.1 of the Agreement, shall be further expanded to also include all the countries in
